What do systematic reviews say?

Psychological interventions vs usual care

Summary of findings: psychological interventions showed no clear difference in lung function FEV1 % predicted compared with usual care (moderate certainty).

• Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  MD 1.4
  1 study · 556 participants
  Moderate

Psychological interventions vs active comparators

The review found no eligible studies for this question.

• Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings for nasal irrigation with topical steroids plus sinus surgery vs nasal irrigation with topical steroids alone

• Surgery for nasal polyposis in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Very low

Wearable fitness tracker plus text message for personalized feedback and goal setting vs wearable fitness tracker alone

• Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 32 participants
  Very low

Web‐based application to record, monitor and set goals on physical activity plus usual care vs usual care

• Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 63 participants
  Low

Web‐based vs face‐to‐face exercise delivery

• Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Digital technology vs usual care

• Digital technology for early identification of exacerbations in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 415 participants
  Moderate

Summary of findings: anti‐pseudomonal antibiotics vs placebo

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 1130 participants
  Low

Summary of findings: anti‐pseudomonal antibiotics vs placebo

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1097 participants
  Low

Summary of findings: tobramycin for inhalation powder vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 517 participants
  Moderate

Summary of findings: aztreonam lysine for inhalation vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 268 participants
  Moderate

Summary of findings: levofloxacin for inhalation solution vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 282 participants
  High

Summary of findings: levofloxacin for inhalation solution vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 282 participants
  High

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 90 participants
  Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 374 participants
  Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 374 participants
  Low

Physical activity vs no physical activity

• Physical activity and exercise training in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 367 participants
  Low

Appetite stimulants vs placebo

• Appetite stimulants for people with cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 42 participants
  Low
• Appetite stimulants for people with cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  Low

Summary of findings: Inhaled antibiotics plus IV antibiotics vs IV antibiotics

• Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 44 participants
  Very low

Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo

• Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25 participants
  Low